Pharmaceutical

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE…

1 year ago

Oxford Biomedica announces CFO transition

Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK –…

1 year ago

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

The Column Group (TCG) led the round with participation from a select group of investorsPrimary sclerosing cholangitis (PSC) is a…

1 year ago

Fortrea Announces Date for Second Quarter 2024 Financial Results and Conference Call

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),…

1 year ago

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells…

1 year ago

BioProcess360 Partners launch dedicated Life Sciences investment fund to grow emerging bioprocessing tools and technologies

Will connect innovators with investment, hands-on expertise and the leading biopharmaceutical manufacturers DELRAY BEACH, Fla., July 17, 2024 (GLOBE NEWSWIRE) --…

1 year ago

Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION17 JULY 2024 at 8.30 EEST              Inside information: Phase III ARANOTE…

1 year ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical…

1 year ago